🌗 Perimenopause & Menopause

What this panel can settle, and by what logic

Split this panel in half and it becomes obvious what you are buying. The hormone half settles very little on its own. The cardiometabolic half settles something permanent, and it is the half nobody buys this panel for.

1. Lipoprotein(a) — Lp(a) is the one result here you will never need again. Lipoprotein(a) is set by genotype and stays roughly flat for life, which is why the European consensus position is to measure it once in every adult Kronenberg 2022. If you buy this panel for the hot flashes and it returns a high Lp(a), the flashes were the cheapest thing about the purchase.
2. ApoB (Apolipoprotein B) beside HbA1c (Hemoglobin A1c) catches a change of trajectory rather than a level. ApoB counts every atherogenic particle, and it disagrees with LDL cholesterol in a substantial minority of people; where the two are discordant, apoB is the one that tracks risk Sniderman 2024. Insulin sensitivity and lipids both shift through the transition, so a value taken now is a baseline for the decade the risk actually accumulates in.
3. TSH (Thyroid-Stimulating Hormone) removes the great imitator. Hypothyroidism and perimenopause are clinically indistinguishable on symptoms, and one of them is treated with a tablet that costs pennies.
4. Ferritin catches the mechanical consequence. Perimenopausal cycles get heavier and less predictable before they stop, and iron stores empty long before a blood count reacts Cancado 2025.

The hormone half — LH & FSH, Estradiol, Sensitive (LC/MS-MS), Progesterone, SHBG (Sex Hormone-Binding Globulin), Total Testosterone — is context for a conversation about treatment, and it is worth having in front of you. It is not the diagnosis.

What it cannot settle, and what would

It cannot diagnose perimenopause, because a single FSH is the wrong instrument for a fluctuating axis. During the transition the ovary responds erratically from one cycle to the next, so gonadotropins and estradiol swing across the whole range within the same woman inside a few months. The diagnosis is made from the bleeding pattern and the symptoms, and a laboratory result changes it rarely Lega 2023. A premenopausal FSH this month does not exclude anything, and a menopausal one does not confirm anything.

Nor can it shorten the wait. Menopause is defined retrospectively, after 12 months without a period. A systematic review of 41 studies covering 28,858 women found that no study had even assessed whether AMH could shorten that 12-month requirement, and that AMH alone could not predict age at menopause with any useful precision — the intervals around those estimates ran from 2 to 12 years in women under 40 Nelson 2023. There is no test on any menu that tells you when.

A low estradiol may be the assay rather than the ovary. Immunoassays lose accuracy at postmenopausal concentrations, which is the reason an Endocrine Society position statement on measuring estradiol exists at all Rosner 2013, and why the sensitive mass-spectrometry method is the one this panel specifies Casals 2023.

And it cannot tell you whether hormone therapy is right for you. That decision runs on symptom burden, time since the final period, blood pressure, migraine history, clot history and personal preference — none of which is on this list Lega 2023. A panel is a useful thing to bring to that appointment. It does not replace it.

Draw conditions that decide whether the money is wasted

The awkward truth about this panel is that its two hormone timings are incompatible with each other, so decide which question you are buying before you book the draw.

1. Still cycling and the question is reserve or menopausal status: days 2 to 5. LH & FSH and Estradiol, Sensitive (LC/MS-MS) are only readable against an early-follicular interval, and a rising follicular estradiol actively suppresses FSH — which means a day-9 draw can return a reassuring FSH produced by the very estradiol you were trying to measure Casals 2023.
2. The question is Progesterone: that is a different tube on a different day. Progesterone is only informative about 7 days after ovulation, and in perimenopause ovulation stops being on day 14. Count back 7 days from when the next period actually arrives rather than forward to day 21, and accept that in an anovulatory cycle the result will be low and will mean nothing more than that this cycle did not ovulate.
3. No period for months: draw any day and say so on the form. With no follicular phase to anchor to, LH & FSH and estradiol are read as levels rather than as cycle positions, which is still useful — a persistently high FSH with a persistently low estradiol in a woman who has not bled for a year is the pattern. It is the persistence that carries the information, not the tube.
4. Fast 9 to 12 hours for ApoB (Apolipoprotein B) and HbA1c (Hemoglobin A1c), and skip the supplement stack for 3 days. Lipoprotein(a) — Lp(a) does not care about any of this, and TSH (Thyroid-Stimulating Hormone) does — biotin and the day-to-day swing in TSH together are enough to move a borderline result across a decision line van der Spoel 2021.

How you would know it answered your question, and what each pattern means next

Six patterns, and the retest intervals below come from how fast the underlying thing can actually move.

• FSH above 25 IU/L with a low Estradiol, Sensitive (LC/MS-MS) and no period for 12 months: the transition is over. Nothing here needs repeating, and the panel's remaining value is entirely in the ApoB (Apolipoprotein B) and Lipoprotein(a) — Lp(a) half.
• One high FSH, periods still happening: the commonest and most misread result. Repeat it in a different cycle if you repeat it at all, because between-cycle variation in the transition is larger than the difference you are looking at Lega 2023.
• An elevated FSH under the age of 40: this is a different diagnosis with its own guideline. Premature ovarian insufficiency turns out to be commoner than previously thought at a prevalence of 3.5%, and the 2024 evidence-based guideline now accepts a single FSH above 25 IU for diagnosis, with a repeat FSH or an Anti-Müllerian Hormone (AMH) reserved for cases where there is genuine uncertainty Panay 2024. Take this to a clinician rather than to another panel.
• TSH (Thyroid-Stimulating Hormone) above 4 mIU/L: repeat before you accept it. Within-person variation means one TSH is a sample from your own distribution, not your set point van der Spoel 2021.
• ApoB (Apolipoprotein B) above target: retest 8 to 12 weeks after any change in diet or medication, which is roughly how long hepatic lipoprotein output takes to reach a new steady state Sniderman 2024. Lipoprotein(a) — Lp(a) is not retested at all.
• Ferritin under 30 ng/mL with heavy erratic bleeding: treat the iron and retest at 12 weeks, and treat the bleeding as its own question rather than as a symptom of the transition Cancado 2025.

Sources read for these sections

• Lega IC, et al. A pragmatic approach to the management of menopause. Canadian Medical Association Journal 2023 · PMID 37188372
• Panay N, et al. Evidence-based guideline: premature ovarian insufficiency. Human Reproduction Open 2024 · PMID 39660328
• Nelson SM, et al. Anti-Mullerian hormone for the diagnosis and prediction of menopause: a systematic review. Human Reproduction Update 2023 · PMID 36651193
• Rosner W, et al. Challenges to the measurement of estradiol: an endocrine society position statement. Journal of Clinical Endocrinology and Metabolism 2013 · PMID 23463657
• Casals G, et al. Recommendations for the measurement of sexual steroids in clinical practice. A position statement of SEQCML/SEEN/SEEP. Advances in Laboratory Medicine 2023 · PMID 37359897
• Sniderman AD, et al. Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention. European Heart Journal 2024 · PMID 38700053
• Kronenberg F, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis. European Heart Journal 2022 · PMID 36036785
• van der Spoel E, et al. Within-Person Variation in Serum Thyrotropin Concentrations: Main Sources, Potential Underlying Biological Mechanisms, and Clinical Implications. Frontiers in Endocrinology 2021 · PMID 33716972
• Cancado RD. Defining Global Thresholds for Serum Ferritin: A Challenging Mission in Establishing the Iron Deficiency Diagnosis in This Era of Striving for Health Equity. Diagnostics (Basel) 2025 · PMID 39941219